These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 546429)

  • 1. Animal model for pharmacokinetic approach to individualized heparin dosage regimen for i.v. infusion by constant rate to achieve and maintain a desired clotting time.
    Ritschel WA; Brady ME
    Arzneimittelforschung; 1979; 29(12):1891-4. PubMed ID: 546429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved methods for estimating initial heparin infusion rates.
    Chenella FC; Gill MA; Kern JW; Floyd RA; McGehee WG
    Am J Hosp Pharm; 1979 Jun; 36(6):782-4. PubMed ID: 463894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-blood activated coagulation time for evaluation of heparin activity during hemodialysis: a comparison of administration by single-dose and by infusion.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1983 Feb; 19(2):82-6. PubMed ID: 6839556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of heparin. II. Studies of time dependence in rats.
    Bjornsson TD; Levy G
    J Pharmacol Exp Ther; 1979 Aug; 210(2):243-6. PubMed ID: 458631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
    Hellebrekers LJ; Slappendel RJ; van den Brom WE
    Am J Vet Res; 1985 Jul; 46(7):1460-2. PubMed ID: 4026027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of a first-order model for estimating initial heparin dosage.
    Joch LE; Lutomski DM; Williams DJ; Bottorff M
    Clin Pharm; 1993 Aug; 12(8):597-601. PubMed ID: 8222524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients.
    Low CL; Bailie G; Morgan S; Eisele G
    Clin Nephrol; 1996 Feb; 45(2):120-4. PubMed ID: 8846524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new route of heparin administration--the lung.
    Kavanagh LW; Jaques LB
    Arzneimittelforschung; 1976; 26(3):389-92. PubMed ID: 989334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of protamine of the prolonged response to intrapulmonary heparin.
    Wright CJ; Mahadoo J; Jaques LB
    Can J Surg; 1981 Mar; 24(2):130-2. PubMed ID: 7225967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemorheological studies of the effect of heparin on the course of coagulation.
    Overholser KA; Baysinger CB; Harris TR; Deveau T
    Thromb Haemost; 1976 Apr; 35(2):447-59. PubMed ID: 989642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics.
    Cipolle RJ; Uden DL; Gruber SA; Jossart GH; Taylor CA; Erdmann GR; Canafax DM
    Pharmacotherapy; 1990; 10(6):367-72. PubMed ID: 2287554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
    Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
    Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long duration of anticoagulant activity and protective effects of acharan sulfate in vivo.
    Li DW; Lee IS; Sim JS; Toida T; Linhardt RJ; Kim YS
    Thromb Res; 2004; 113(1):67-73. PubMed ID: 15081567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of local heparin infusion in a canine renal allograft model.
    Gruber SA; Cipolle RJ; Tzardis P; Skjei KL; Jossart G; Abed JF; Canafax DM; Burke BA; Matas AJ; Hrushesky WJ
    J Pharmacol Exp Ther; 1990 Feb; 252(2):733-8. PubMed ID: 2313597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic heparin anticoagulant in dogs by continuous infusion with a totally implantable pump.
    Rhode TD; Blachshear PJ; Varco RL; Buchwald H
    Trans Am Soc Artif Intern Organs; 1975; 21():510-5. PubMed ID: 1146026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of cyclosporine. I. Single dose and constant rate infusion studies in the rabbit.
    Awni WM; Sawchuk RJ
    Drug Metab Dispos; 1985; 13(2):127-32. PubMed ID: 2859157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
    Gentry WB; Krejcie TC; Henthorn TK; Shanks CA; Howard KA; Gupta DK; Avram MJ
    Anesthesiology; 1994 Aug; 81(2):316-24; discussion 25A. PubMed ID: 8053580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic model for intravenous heparin infusion.
    Bauwens S; Dukes GE
    Am J Hosp Pharm; 1980 Jan; 37(1):26, 31, 37 passim. PubMed ID: 7361772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.